|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0017262,
umls-concept:C0029005,
umls-concept:C0033325,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0205160,
umls-concept:C0205373,
umls-concept:C0746922,
umls-concept:C1522673,
umls-concept:C1706163,
umls-concept:C2697524,
umls-concept:C2700445,
umls-concept:C2911684
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1993-12-16
|
|
pubmed:abstractText |
In a retrospective study, paraffin-embedded tissues from 110 primary T1 breast carcinomas (tumour diameter < or = 2 cm) were examined for the presence of the Her-2/neu encoded oncoprotein p185neu, using an immunohistochemical technique. Primary surgical therapy revealed no node involvement in 76 cases. These patients did not receive an adjuvant systemic therapy. 25% of tumours were positive for p185neu. Expression of the oncoprotein was inversely correlated to oestrogen receptor status (p < 0.05). In patients with lymph node metastases and poorly differentiated tumours, the incidence of p185neu was higher than in node negative and/or well differentiated carcinomas. However, this finding was statistically not significant. No correlations were found between the detection of the oncoprotein and age, menopausal and progesterone receptor status. The median follow-up is 85 months. In patients without lymph node metastases (n = 76), presence of the oncoprotein was significantly correlated to a shorter relapse-free and/or overall survival (p < 0.05). No such correlation was found for 34 patients with lymph node involvement. Expression of p185neu seems to mark a group of T1N0 breast cancer patients, which is at high risk and might benefit from an adjuvant therapy.
|
|
pubmed:language |
ger
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0016-5751
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:geneSymbol |
p185neu
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
625-9
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:7901111-Adult,
pubmed-meshheading:7901111-Aged,
pubmed-meshheading:7901111-Breast Neoplasms,
pubmed-meshheading:7901111-Chemotherapy, Adjuvant,
pubmed-meshheading:7901111-Combined Modality Therapy,
pubmed-meshheading:7901111-Female,
pubmed-meshheading:7901111-Follow-Up Studies,
pubmed-meshheading:7901111-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:7901111-Humans,
pubmed-meshheading:7901111-Lymphatic Irradiation,
pubmed-meshheading:7901111-Lymphatic Metastasis,
pubmed-meshheading:7901111-Mastectomy, Segmental,
pubmed-meshheading:7901111-Middle Aged,
pubmed-meshheading:7901111-Neoplasm Staging,
pubmed-meshheading:7901111-Prognosis,
pubmed-meshheading:7901111-Proto-Oncogene Proteins,
pubmed-meshheading:7901111-Receptor, Epidermal Growth Factor,
pubmed-meshheading:7901111-Receptor, erbB-2,
pubmed-meshheading:7901111-Receptors, Estrogen,
pubmed-meshheading:7901111-Receptors, Progesterone,
pubmed-meshheading:7901111-Retrospective Studies,
pubmed-meshheading:7901111-Survival Rate
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
[Expression of the p185neu oncoprotein indicates an unfavorable prognosis in small, node negative breast cancer without systemic adjuvant treatment (T1N0)].
|
|
pubmed:affiliation |
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universität zu Köln.
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
